Travere Therapeutics highlights advancements in rare kidney and metabolic disease therapies in new corporate overview

Reuters11-01

Travere <a href="https://laohu8.com/S/LENZ">Therapeutics</a> highlights advancements in rare kidney and metabolic disease therapies in new corporate overview

Travere Therapeutics Inc. has published a corporate presentation outlining its latest strategic priorities and milestones for 2025. The company highlighted its focus on rare kidney and metabolic diseases, with FILSPARI positioned as foundational care in IgA nephropathy (IgAN) and a pending FDA decision for its use in focal segmental glomerulosclerosis $(FSGS)$, with a PDUFA target action date of January 13, 2026. Updates include the inclusion of FILSPARI in the final 2025 KDIGO guidelines for earlier, first-line use in IgAN, and recent FDA changes reducing liver monitoring requirements and removing the embryo-fetal toxicity REMS requirement for the therapy. The presentation also notes ongoing development of pegtibatinase and plans for further growth through clinical development and external innovation. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief on October 31, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2580798443?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-01 09:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580798443","market":"nz","top_or_hot":-1,"title":"Travere Therapeutics highlights advancements in rare kidney and metabolic disease therapies in new corporate overview","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Travere <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> highlights advancements in rare kidney and metabolic disease therapies in new corporate overview\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Travere Therapeutics Inc. has published a corporate presentation outlining its latest strategic priorities and milestones for 2025. The company highlighted its focus on rare kidney and metabolic diseases, with FILSPARI positioned as foundational care in IgA nephropathy (IgAN) and a pending FDA decision for its use in focal segmental glomerulosclerosis <a href=\"https://laohu8.com/S/FSGS\">$(FSGS)$</a>, with a PDUFA target action date of January 13, 2026. Updates include the inclusion of FILSPARI in the final 2025 KDIGO guidelines for earlier, first-line use in IgAN, and recent FDA changes reducing liver monitoring requirements and removing the embryo-fetal toxicity REMS requirement for the therapy. The presentation also notes ongoing development of pegtibatinase and plans for further growth through clinical development and external innovation. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief on October 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Travere Therapeutics highlights advancements in rare kidney and metabolic disease therapies in new corporate overview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTravere Therapeutics highlights advancements in rare kidney and metabolic disease therapies in new corporate overview\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-01 09:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Travere <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> highlights advancements in rare kidney and metabolic disease therapies in new corporate overview\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Travere Therapeutics Inc. has published a corporate presentation outlining its latest strategic priorities and milestones for 2025. The company highlighted its focus on rare kidney and metabolic diseases, with FILSPARI positioned as foundational care in IgA nephropathy (IgAN) and a pending FDA decision for its use in focal segmental glomerulosclerosis <a href=\"https://laohu8.com/S/FSGS\">$(FSGS)$</a>, with a PDUFA target action date of January 13, 2026. Updates include the inclusion of FILSPARI in the final 2025 KDIGO guidelines for earlier, first-line use in IgAN, and recent FDA changes reducing liver monitoring requirements and removing the embryo-fetal toxicity REMS requirement for the therapy. The presentation also notes ongoing development of pegtibatinase and plans for further growth through clinical development and external innovation. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief on October 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TVTX","symbol_name":"Travere Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251101:nNDLc3QK3H:1","article_id":"2580798443","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580798443","pubTimestamp":1761959161,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Travere Therapeutics Inc. has published a corporate presentation outlining its latest strategic priorities and milestones for 2025. The company highlighted its focus on rare kidney and metabolic diseases, with FILSPARI positioned as foundational care in IgA nephropathy  and a pending FDA decision for its use in focal segmental glomerulosclerosis , with a PDUFA target action date of January 13, 2026. Updates include the inclusion of FILSPARI in the final 2025 KDIGO guidelines for earlier, first-line use in IgAN, and recent FDA changes reducing liver monitoring requirements and removing the embryo-fetal toxicity REMS requirement for the therapy. The presentation also notes ongoing development of pegtibatinase and plans for further growth through clinical development and external innovation. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accu","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TVTX":"Travere Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Travere Therapeutics在新的公司概述中强调了罕见肾脏和代谢疾病疗法的进步","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TVTX":0.9},"content_text":"Travere Therapeutics highlights advancements in rare kidney and metabolic disease therapies in new corporate overview\n    \n\n        Travere Therapeutics Inc. has published a corporate presentation outlining its latest strategic priorities and milestones for 2025. The company highlighted its focus on rare kidney and metabolic diseases, with FILSPARI positioned as foundational care in IgA nephropathy (IgAN) and a pending FDA decision for its use in focal segmental glomerulosclerosis $(FSGS)$, with a PDUFA target action date of January 13, 2026. Updates include the inclusion of FILSPARI in the final 2025 KDIGO guidelines for earlier, first-line use in IgAN, and recent FDA changes reducing liver monitoring requirements and removing the embryo-fetal toxicity REMS requirement for the therapy. The presentation also notes ongoing development of pegtibatinase and plans for further growth through clinical development and external innovation. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief on October 31, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2580798443","isCrawlerRequest":true}